Navigation Links
Insmed CEO to Present at Drug Discovery & Development Conference
Date:7/25/2008

CEO Geoffrey Allan Will Discuss Company's IPLEX(TM) Program in Myotonic

Muscular Dystrophy

RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics on Thursday, August 7th, 2008 at 9:25 AM ET.

Dr. Allan will be participating in the Orphan Diseases track of the conference and his presentation will be entitled, "Myotonic Muscular Dystrophy - A Major Unmet Medical Need." He will present Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, which has seen strong patient and physician interest, is now fully enrolled. It is a six month, randomized, double-blind, placebo-controlled trial being conducted at 13 research centers across the U.S.

The conference will be held from August 4th to August 7th, 2008, at the World Trade Center Boston and the Seaport Hotel in Boston, MA.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed to Host Second Quarter 2008 Conference Call
2. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
3. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
4. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
5. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
6. Insmed Announces First Quarter 2008 Financial Results
7. Insmed to Present at CBI Follow-On Biologics Conference
8. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... HACKENSACK, N.J. , Jan. 18, 2017   ... leading the fight to end Duchenne muscular dystrophy ... awarded to the New Jersey Institute of Technology (NJIT) ... ongoing exploration of robotic technology to assist ... study to incorporate NJIT,s technology – an embedded computer, ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... more and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific ... the past year and is planned for further growth in 2017. Extractable & ...
(Date:1/18/2017)... ... January 18, 2017 , ... Researchers from a new study are stating that ... enough after prostate cancer treatment, this indicates there is still remaining prostate cancer cells that ... “ The PSA test has always been an indicator of whether a man’s prostate cancer ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the leading microbial ... its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue of the ... uBiome in October 2016 from her previous position at Stanford University School of ...
Breaking Biology Technology:
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
Breaking Biology News(10 mins):